Join Foghorn Therapeutics for a virtual investor event to review key development updates for its Selective ARID1B degrader program which will be presented as part of a Keynote Plenary session at the 8th Annual TPD and Induced Proximity Summit being held October 27-30, 2025, in Boston, MA.

The Company will share the continued momentum for their Selective ARID1B, Selective CBP and Selective EP300 degrader programs, which are steadily progressing toward Investigational New Drug (IND) enabling studies. These collective developments reflect the potential of Foghorn’s protein degrader capabilities to expand therapeutic possibilities in areas with limited treatment innovation.

A live question and answer session will follow the formal presentations.